#bictegravir
LightNews LightNews
cidjournal.bsky.social
Bictegravir Use During Pregnancy: A Multicenter Retrospective Analysis Evaluating HIV Viral Suppression and Perinatal Outcomes

⭐ Editor's Choice
#IDSky
Bictegravir Use During Pregnancy: A Multicenter Retrospective Analysis Evaluating HIV Viral Suppression and Perinatal Outcomes
This study describes the largest cohort to date (n = 147) of pregnant patients with human immunodeficiency virus (HIV) on bictegravir (BIC).
buff.ly
December 14, 2024 at 7:58 PM
cidrap.bsky.social
Novel 1-pill regimen tamps down virus in older adults with HIV, study suggests

The regimen combining bictegravir and lenacapavir provided similar viral suppression as multi-pill antiretroviral therapy

www.cidrap.umn.edu/h...
February 25, 2026 at 7:15 PM
absteward.bsky.social
🆕💥Exciting news
U.S. FDA Grants Priority Review of New Drug Application for Gilead’s once-daily single-tablet combination(Bictegravir Plus Lenacapavir) regimen for the treatment of HIV in adults who are virologically suppressed
PDUFA: August 27, 2026 #idsky
www.gilead.com/news/news-de...
U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once Daily HIV Treatment of Bictegravir Plus Lenacapavir
U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once Daily HIV Treatment of Bictegravir Plus Lenacapavir
www.gilead.com
April 30, 2026 at 10:25 AM
ohnosven.bsky.social
Bonus edition:
-emtricitabina
-tenofovir alafenamide
-bictegravir
December 24, 2024 at 8:56 PM
absteward.bsky.social
🆕💥🔴ARTISTRY-2 RCT
Safety and efficacy of switching to bictegravir–lenacapavir versus continuing bictegravir–emtricitabine–tenofovir alafenamide in virologically suppressed people with HIV-1 #IDSky #HIVSky
www.thelancet.com/journals/lan...
Safety and efficacy of switching to bictegravir–lenacapavir versus continuing bictegravir–emtricitabine–tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind...
Bictegravir–lenacapavir has the potential to be a novel single-tablet antiretroviral regimen option for virologically suppressed people with HIV-1.
www.thelancet.com
May 7, 2026 at 2:32 AM
cidjournal.bsky.social
Real-world Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Comparison With Other Regimens in People With Human Immunodeficiency Virus Starting Therapy With AIDS-Defining Conditions

#IDSky
Real-world Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Comparison With Other Regimens in People With Human Immunodeficiency Virus Starting Therapy With AIDS-Defining Conditions
The comparative effectiveness and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) has not been sufficiently evaluated in people with AIDS who initiate therapy.
academic.oup.com
April 27, 2025 at 6:58 PM
scooper-id.bsky.social
Doravirine/Islatravir Noninferior To Bictegravir/Emtricitabine/Tenofovir Alafenamide As First-Line ART For Patients With HIV, (Study)
#IDSky #HIV

academic.oup.com/cid/advance-...
Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial Human Immunodeficiency Virus Type 1 Treatment: 48-Week Results From a Phase 3, R...
Doravirine/islatravir (100/0.75 mg) was noninferior to bictegravir/emtricitabine/tenofovir alafenamide in suppressing human immunodeficiency virus type 1 (
academic.oup.com
June 3, 2025 at 12:11 PM
infectiobxl.bsky.social
In last @cidjournal.bsky.social issue, "Bictegravir Use During Pregnancy: A Multicenter Retrospective Analysis Evaluating HIV Viral Suppression and Perinatal Outcomes"
Reassuring data.
#HIVSky #IDSky

academic.oup.com/cid/article/...
Bictegravir Use During Pregnancy: A Multicenter Retrospective Analysis Evaluating HIV Viral Suppression and Perinatal Outcomes
Abstract. This study describes the largest cohort to date (n = 147) of pregnant patients with human immunodeficiency virus (HIV) on bictegravir (BIC). BIC
academic.oup.com
November 22, 2024 at 7:33 PM
doutormaravilha.bsky.social
Boa notícia pra quem vive com HIV no Brasil!
A CONITEC aprovou o uso do Biktarvy®️ (bictegravir + emtricitabina + tenofovir alafenamida) no SUS.

Um único comprimido, potente, com menos efeitos colaterais e menor impacto nos rins e ossos em relação ao esquema anterior com tenofovir tradicional.
October 7, 2025 at 10:44 AM
scooper-id.bsky.social
Single-Tablet Bictegravir/Lenacapavir Effective After Treatment Switch #IDSky #HIV

www.ajmc.com/view/single-...
Single-Tablet Bictegravir/Lenacapavir Effective After Treatment Switch | AJMC
Topline results find that single-tablet regimen of bictegravir/lenacapavir had noninferior efficacy when patients switched from multitablet regimens in HIV.
www.ajmc.com
November 17, 2025 at 1:29 PM
drlaurajwaters.bsky.social
@brendacrabtreer.bsky.social makes excellent point in excellent closing session on INSTI resistance. We should talk about 'INSTI resistance' not 'DTG resistance'. Some LMIC have bictegravir too you know....! And much INSTI resistance is due to prior exposure to 1st generation INSTI too....
#CROI2025
March 13, 2025 at 12:11 AM
aidsmap.bsky.social
News from CROI 2026: Bictegravir/lenacapavir combination pill could be an option for people taking complex regimens #CROI2026
Bictegravir/lenacapavir combination pill could be an option for people taking complex regimens
A once-daily combination pill containing bictegravir and lenacapavir could offer a simpler alternative for people with HIV who are taking complex antiretroviral regimens, according to study results presented yesterday at the Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver.
www.aidsmap.com
February 26, 2026 at 7:56 PM
lizhighleyman.bsky.social
Gilead's new once-daily single-tablet regimen containing bictegravir & lenacapavir could offer a simpler alternative for people with HIV who are currently on complex antiretroviral regimens -- especially older people managing comorbidities & multiple meds.

www.poz.com/article/fda-...
FDA Approves Bixlenvo, a New Daily HIV Combination Pill
The single-tablet regimen containing bictegravir and lenacapavir is a new option for people switching from complex antiretroviral regimens.
www.poz.com
August 28, 2026 at 12:53 AM
vtrosa.bsky.social
e recordem criancas, se vc toma dolutegravir uo bictegravir de retro nao pode tomar zinc muito proximo ou depois de tomarlos.

dolutegravir ou bictegravir con zinc NAO PODCHYYYYY
September 14, 2026 at 4:37 PM
ebtapper.bsky.social
In this study 25 patients switched from a non-nucleoside reverse tran-scriptase inhibitor-based regimen to bictegravir/emtricitabine/TAF

And their liver fat was substantially decreased on serial fibroscan

www.mdpi.com/1999-4915/17...

#liversky #idsky
www.mdpi.com
March 30, 2025 at 11:39 PM
cidjournal.bsky.social
Doravirine/islatravir (100/0.75 mg) once-daily compared to bictegravir/emtricitabine/tenofovir alafenamide as initial HIV-1 treatment: 48-week results from a phase 3, randomized, controlled, double-blind, non-inferiority trial

✅ Just Accepted
⭐ Editor's Choice
#IDSky
Doravirine/islatravir (100/0.75 mg) once-daily compared to bictegravir/emtricitabine/tenofovir alafenamide as initial HIV-1 treatment: 48-week results from a phase 3, randomized, controlled, double-blind, non-inferiority trial
Doravirine/islatravir is an investigational, once-daily regimen being studied for HIV-1 treatment.
doi.org
March 18, 2025 at 12:41 PM
ofidjournal.bsky.social
Three Year Efectiveness of Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategy in the Real-World

✅ Just Accepted
#IDSky
Three Year Efectiveness of Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategy in the Real-World
We previously described the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide as a switch strategy in real-life in people with HIV (PWH) at 48 weeks.
buff.ly
March 5, 2025 at 5:01 PM
petraflint.bsky.social
The FDA has approved Bixlenvo as a once-daily single-tablet regimen for virologically suppressed adults living with HIV. The drug is particularly notable for patients previously managing more complicated treatment regimens.
FDA Approves Bixlenvo Once-Daily Single-Tablet Regimen for Virologically Suppressed Adults With HIV | Pharmacy Times
Bictegravir/lenacapavir (Bixlenvo) offers the first single-tablet option for many patients with HIV currently receiving complex antiretroviral regimens.
www.pharmacytimes.com
August 28, 2026 at 9:21 PM
paulsaxmd.bsky.social
When we care for PWH who have virologic suppression, but possible or confirmed NRTI resistance, can we switch them to a simple oral treatment -- once-daily BIC/FTC/TAF? This study says yes, with results strengthened by proviral DNA testing. #IDSky #HIVSky www.sciencedirect.com/science/arti...
Bictegravir, emtricitabine, and tenofovir alafenamide versus ritonavir-boosted protease inhibitor-based antiretroviral therapy in people with HIV and viral suppression on second-line therapy in Haiti:...
Patients on second-line protease inhibitor-based regimens in low-income and middle-income countries have high rates of nucleoside reverse transcriptas…
www.sciencedirect.com
August 28, 2025 at 12:07 AM
mitchdumais.bsky.social
Now FDA approved! Bictegravir-Lenacapavir (BIC/LEN) daily pill for HIV+ patients who are suppressed and likely on more complex regimens.

Another option for patients with kidney disease, NNRTI/NRTI resistance.

Trial Here:
ARTISTRY-1: The Lancet www.thelancet.com/journals/lan...
Switch to single-tablet bictegravir–lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial
Bictegravir–lenacapavir STR demonstrated non-inferior efficacy to complex regimens, with a similar safety profile and increased treatment satisfaction. Bictegravir–lenacapavir offers new opportunities...
www.thelancet.com
August 28, 2026 at 2:47 PM
hassan.blacksky.app
If you're in Florida (or anywhere) and these cuts are impacting you, almost every major drug manufacturer has a PAP (Patient Assistance Program). Gilead has one for Biktarvy that will cover almost $8k in co-pays for free. shorturl.at/jg0Tm

Don't let bureaucracy scare you out of treatment!
January 16, 2026 at 3:51 PM
castltrastondrs.medsky.network
#medsky #idsky #pharmasky #clinicaltrial #immunosky #Publichealth #Doravirine/islatravir (100/0.75 mg) once-daily was non-inferior to #bictegravir/emtricitabine/tenofoviralafenamide through week 48 for initial #HIV-1 treatment.
March 18, 2025 at 2:18 PM
infdiseasesnow.bsky.social
[Publication] The article "Bictegravir use during pregnancy" is now available.

www.sciencedirect.com/science/arti...

#IDsky #Pregnancy #Bictegravir
Bictegravir use during pregnancy
www.sciencedirect.com
May 19, 2025 at 10:51 AM
cidjournal.bsky.social
Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults with HIV (INSTINCT/GESIDA10918 Study)

✅ Just Accepted
#IDSky
🔗 https://bit.ly/3IV6tvN
October 15, 2025 at 4:01 PM
medpagetoday.com
The FDA approved the combination of bictegravir and lenacapavir (Bixlenvo) for adults with virologically suppressed HIV-1 infection, Gilead Sciences announced Thursday.
https://www.medpagetoday.com/infectiousdisease/hivaids/122817
Bictegravir-Lenacapavir Combo Pill Earns FDA Approval in Suppressed HIV
Combo could offer an alternative for those who can't take existing single-tablet regimens
www.medpagetoday.com
August 28, 2026 at 9:10 PM